Dr. Wyatt receives CCS Impact Grant for prostate cancer precision oncology

Dr. Alex Wyatt has been awarded a Canadian Cancer Society Impact Grant for his project, "Practical genomic stratification to enable tailored treatment of DNA repair defective prostate cancer." This five-year project will screen blood samples from metastatic castration-resistant prostate cancer patients across Canada in order to identify the subset whose tumours are defective in specific classes of DNA damage repair. These patients will be selectively treated on the basis of their results, using chemotherapy or immunotherapy. By combining genomic screening expertise with a national clinical trial network, the goal is to improve Canadian patient access to emerging therapies and advance a precision-medicine approach to care.

Dr. Wyatt's grant and the eight other awarded projects are listed at the Canadian Cancer Society website.